Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D A Andreev

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Terapevticheskii Arkhiv|April 27, 2004
[Activity of myocardial sympathetic-adrenal system with various volume of viable myocardium in patients with chronic cardiac failure]V G Kukes, D A Sychev, D A Andreev, et al.
Klinicheskaia Meditsina|August 2, 2007
[The effects of beta-adrenoblocker therapy on the physical working capacity of patients with chronic heart failure of various origin]M G Poltavskaia, A L Syrkin, D A Andreev, et al.
Kardiologiia|December 15, 2022
Predictors of tachycardia-induced cardiomyopathy in patients with first-time decompensation of chro-nic heart failure with reduced left ventricular ejection fraction of nonischemic etiology and persistent atrial tachyarrhythmiaO S Orlov, A Asfour, A A Bogdanova, et al.
Rossiiskii Fiziologicheskii Zhurnal Imeni I.M. Sechenova|December 5, 2009
[Prognostic, diagnostic, and therapeutic prospects of using adiponectine as a biomarker in cardiobascular diseases]E M Pal'tseva, A V Rodina, S V Konstantinova, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|February 27, 2023
[Clinical features of asthenic disorders in chronic heart failure]A V Fomicheva, B A Volel, D V Troshina, et al.
Kardiologiia|April 10, 2024
Determining The Risk of Atrial Fibrillation Paroxysm in Patients With Chronic Heart Failure With Intact and Reduced Ejection FractionI P Zakharov, P Sh Chomakhidze, F Yu Kopylov, et al.
Klinicheskaia Laboratornaia Diagnostika|August 26, 2010
[Urokinase-type plasminogen activator and its inhibitor type 1 in the diagnosis of evolving complications in coronary heart disease]E M Pal'tseva, A V Rodina, D A Andreev, et al.
Kardiologiia|February 4, 2019
O A Baturina, D A Andreev, N A Ananicheva, et al.
Kardiologiia|April 30, 2020
[Prevalence of Advanced Chronic Kidney Disease in Patients with Nonvalvular Atrial Fibrillation Hospitalized in Cardiology Departments]M I Chashkina, N L Kozlovskaya, D A Andreev, et al.
Molecular Biology Reports|May 19, 2019
Genotyping and phenotyping CYP3A4\CYP3A5: no association with antiplatelet effect of clopidogrelK B Mirzaev, K I Samsonova, P P Potapov, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Terapevticheskii Arkhiv|April 27, 2004
[Activity of myocardial sympathetic-adrenal system with various volume of viable myocardium in patients with chronic cardiac failure]V G Kukes, D A Sychev, D A Andreev, et al.
Klinicheskaia Meditsina|August 2, 2007
[The effects of beta-adrenoblocker therapy on the physical working capacity of patients with chronic heart failure of various origin]M G Poltavskaia, A L Syrkin, D A Andreev, et al.
Kardiologiia|December 15, 2022
Predictors of tachycardia-induced cardiomyopathy in patients with first-time decompensation of chro-nic heart failure with reduced left ventricular ejection fraction of nonischemic etiology and persistent atrial tachyarrhythmiaO S Orlov, A Asfour, A A Bogdanova, et al.
Rossiiskii Fiziologicheskii Zhurnal Imeni I.M. Sechenova|December 5, 2009
[Prognostic, diagnostic, and therapeutic prospects of using adiponectine as a biomarker in cardiobascular diseases]E M Pal'tseva, A V Rodina, S V Konstantinova, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|February 27, 2023
[Clinical features of asthenic disorders in chronic heart failure]A V Fomicheva, B A Volel, D V Troshina, et al.
Kardiologiia|April 10, 2024
Determining The Risk of Atrial Fibrillation Paroxysm in Patients With Chronic Heart Failure With Intact and Reduced Ejection FractionI P Zakharov, P Sh Chomakhidze, F Yu Kopylov, et al.
Klinicheskaia Laboratornaia Diagnostika|August 26, 2010
[Urokinase-type plasminogen activator and its inhibitor type 1 in the diagnosis of evolving complications in coronary heart disease]E M Pal'tseva, A V Rodina, D A Andreev, et al.
Kardiologiia|February 4, 2019
O A Baturina, D A Andreev, N A Ananicheva, et al.
Kardiologiia|April 30, 2020
[Prevalence of Advanced Chronic Kidney Disease in Patients with Nonvalvular Atrial Fibrillation Hospitalized in Cardiology Departments]M I Chashkina, N L Kozlovskaya, D A Andreev, et al.
Molecular Biology Reports|May 19, 2019
Genotyping and phenotyping CYP3A4\CYP3A5: no association with antiplatelet effect of clopidogrelK B Mirzaev, K I Samsonova, P P Potapov, et al.
Pageof 5